drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy
drug_description
Autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy administered as a single intravenous infusion to deplete CD19+ B-lineage cells and reduce pathogenic autoantibodies in generalized myasthenia gravis.
nci_thesaurus_concept_id
C203740
nci_thesaurus_preferred_term
Autologous Anti-CD19 CAR-T Cells CABA-201
nci_thesaurus_definition
A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the B-lymphocyte antigen CD19, coupled to a costimulatory domain of 4-1BB (CD137), with potential immunomodulatory activity. Upon administration, autologous anti-CD19 CAR-T cells CABA-201 target and bind to CD19-expressing B-cells. This results in a cytotoxic T-lymphocyte (CTL) response against CD19-expressing B-cells. CD19, a B-cell-specific cell surface antigen that plays an important role in B-cell activation, is overexpressed in some autoimmune diseases.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Immunotherapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically modified to express an anti-CD19 chimeric antigen receptor with 4-1BB costimulation. After infusion, these CAR-T cells recognize CD19 on B-lineage cells and mediate cytotoxic killing, depleting B cells and plasmablasts to reduce pathogenic autoantibody production in generalized myasthenia gravis.
drug_name
CABA-201
nct_id_drug_ref
NCT06359041